Posts Tagged ‘research’
Interested in a Career with Oncology Clinical Research?
Stephanie Van Bebber is a certified clinical research professional. She serves as the Senior Director of the Clinical Trials Office for Inova Schar Cancer Institute. We don’t need to scroll very far to see that healthcare is facing major challenges, especially in our human resources. We need more people to train and commit to careers…
Read MoreData from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
Falls Church, VA – Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19, in Clinical Infectious Diseases, an official publication of the Infectious Disease Society of America. The study was sponsored by the National…
Read MoreDiversity and Inclusion in Clinical Trials
Stephanie Van Bebber is Senior Director, Inova Schar Cancer Institute Clinical Trials Office at Inova. As we celebrate Clinical Trials Day this year, we recognize the extraordinary work that is done by research teams every day to ensure that future healthcare treatments and interventions are safe and effective. The date of May 20th honors James…
Read MoreInova’s Breast Cancer Team Takes a New Look at Hormone Therapy Treatment
A group of six Inova physicians have published a paper in the Annals of Surgical Oncology that could lead to re-thinking of treatment practices for individuals with breast cancer. The paper, published in November 2020, details the results of a systemic literature review that included over 6,000 patient cases. READ THE REPORT: Axillary Response in…
Read MoreReview of Inova COVID-19 Cases Lends Insight into Ventilator Mortality Risks
Falls Church, VA – An Inova study of COVID-19 patients sheds light on how patients have responded to advanced ICU interventions. Researchers sought to paint a realistic picture of survival expectations within a single, well-resourced healthcare system, over the patient’s entire length of stay. Christopher King, MD, transplant pulmonologist and critical care physician at Inova Fairfax…
Read MoreInova’s Dr. Aragon-Ching Part of International Team Showing Benefit of Immunotherapy in Bladder Cancer Treatment
Jeanny B. Aragon-Ching, MD of the Inova Schar Cancer Institute has co-authored a groundbreaking bladder cancer research paper just published in the New England Journal of Medicine. The large phase III clinical study showed that the addition of immunotherapy with Avelumab (Bavencio) increased the duration of overall survival by almost 50% in patients when given…
Read MoreInova Joins Virginia Department of Health and George Mason University in Pediatric COVID-19 Serology Study
Inova Health System is partnering with George Mason University (GMU) and the Virginia Department of Health (VDH) to conduct a COVID-19 serology (antibody) study to analyze the incidence of COVID-19 in children in Northern Virginia. Inova is recruiting approximately 1,000 children, ages 0 to 19 for the study. Child participants will be asked to provide…
Read MoreBladder Cancer Discovery: Immunotherapy as Maintenance Treatment
Bladder cancer is the sixth most common cancer in the United States. Bladder cancer is usually diagnosed at “superficial” or non-invasive stages, when it only involves the lining of the bladder and can be treated with removal of the cancerous tissue alone. However, some patients develop high-risk tumors that are likely to come back and…
Read MoreSports Medicine Research: Pushing Limits to Improve Patient Care
Medical treatments should always be based on the best available evidence. But sometimes, the best evidence isn’t good enough. “We should always be looking to get better,” said Edward Chang, MD, an orthopedic surgeon and researcher at Inova Sports Medicine. That mission is why Inova Sports Medicine investigators are working on a number of exciting…
Read MoreFDA Approves Cutting-Edge Cancer Drug from Inova Schar Cancer Institute Clinical Trial
Inova’s Dr. John Deeken served as the site principal investigator for this prestigious study In groundbreaking news for the medical and cancer research community, the Food and Drug Administration (FDA) approved a new, breakthrough cancer drug, larotrectinib, or Vitrakvi®, that targets specific genetic mutations in adult and pediatric patients. This is only the second tissue-agnostic…
Read More